ClinicalTrials.Veeva

Menu

Rational Approach to a Unilateral Pleural Effusion2 (REPEAT)

S

Simon Reuter

Status

Terminated

Conditions

Lung Neoplasms

Treatments

Device: PET-CT
Device: Contrast-enhanced CT

Study type

Interventional

Funder types

Other

Identifiers

NCT02834455
Resp-REPEAT-SIRE

Details and patient eligibility

About

Recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary pleural malignancy. Both conditions are associated with 5-year survival of 10%. Work-up is difficult, as the pleural surface is large and <33% of pleural malignancies shed malignant cells to the pleural fluid. Even so, additional tissue biopsies are needed for establishing mutation status for targeted therapies.

Optimal imaging to guide tissue sampling is pivotal. PET-CT has higher sensitivity than conventional CT for detecting malignant lesions >10mm. However, no randomised trial has investigated differences in diagnostic accuracy, time-to-diagnosis, or economics. Falsely PET-positive lesions in e.g. colon however, lead to more derived tests than do CT alone.

Gold standard for pleural tissue sampling is the surgical (VATS) thoracoscopy, allowing direct visual guiding of tissue sampling from all pleural surfaces. Yet, globally the medical (pleuroscopy) thoracoscopy is more widely used: cheaper, outpatient procedure, but allows only sampling from the parietal pleura. To date, no randomised studies have compared medical and surgical thoracoscopy concerning diagnostic hit rates, adverse events, or economics.

The investigators will perform two randomized studies to investigate whether

  1. PET/CT is comparable to CT alone
  2. VATS is comparable to pleuroscopy concerning hit rate, total investigations performed, time-to-diagnosis.

Enrollment

200 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines.
  2. Indication for thoracoscopy according to BTS guidelines.
  3. Patients accept further investigation according to Danish and BTS guidelines.
  4. Have received oral and written consent and agreed.
  5. At the time of inclusion, above 18 years of age.

Exclusion criteria

  1. Female patients: pregnancy or breastfeeding.
  2. Lack of language comprehension.
  3. Legally incompetent patients.
  4. Life expectancy less than 3 month.
  5. Contraindications to pleural tissue sampling.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

CE-CT scanning
Active Comparator group
Description:
Contrast-enhanced CT scan of the thorax and abdomen.
Treatment:
Device: Contrast-enhanced CT
PET-CT scanning
Active Comparator group
Description:
Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
Treatment:
Device: PET-CT

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems